A message from MMV's CEO, David Reddy
As 2016 draws to a close, it’s humbling to reflect on the latest estimate that MMV partnership drugs have saved the lives of over a million young people since the launch of our first co-developed antimalarial in 2009. Over the year we have helped further increase the uptake of life-saving malaria drugs, addressed supply bottlenecks, discovered and progressed the next generation of antimalarial medicines, forged new partnerships and strengthened existing ones, and continued to raise the funds necessary to fuel our mission.
Details follow in the 2016 review document below.
We send you heartfelt thanks for supporting our work and wish you the very best for 2017.